Immunohistochemical expression and prognostic significance of VEGF-C in well-differentiated thyroid cancer.
VEGF-C thyroid
angiogenesis
thyroid cancer
Journal
Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720
Informations de publication
Date de publication:
Historique:
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
ppublish
Résumé
Neoangiogenesis and lymphangio-genesis are essential for the growth of tumor and progression of malignancy. The study examined the significance of VEGF-C expression in comparison to classical prognostic factors in differentiated thyroid carcinoma (DTC), as well as an independent prognostic marker in DTC. The study included 81 patients with DTC allocated in two groups according to the type of cancer (follicular Expression of VEGF-C was identified with anti-VEGF-C antibody using tris-EDTA buffer Antigen Retrieval Protocol. Each specimen was scored with a semi-quantitative score system (H-score). The analysis of T staging system showed a linear correlation between the size of a tumor, expression of VEGF-C and recurrence of a disease, with a statistical significance (p < 0.0001). There was a clear and significant correlation between VEGF-C expression and T stage in patients with papillary carcinoma (p = 0.0294). Analysis of invasion of a surgical margin demonstrated significant positivity in patients with papillary thyroid cancers who expressed VEGF-C (p = 0.0207) indicating the worse prognosis of a disease. Also a statistically significant correlation was between VEGF-C and extrathyroid extension, indicating the worse prognosis (p = 0.0133) in papillary cancers. The level of VEGF-C expression was statistically significant in patients with papillary thyroid cancer (p = 0.039). This study undoubtedly demonstrates that VEGF-C expression is an evident negative prognostic factor in patients with papillary thyroid carcinoma, along with the classic prognostic factors, such as a larger tumor size, tumor margin involvement, extrathyroid extension, i.e. local aggressiveness.
Identifiants
pubmed: 34084231
doi: 10.4183/aeb.2020.409
pii: aeb.2020.409
pmc: PMC8126380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
409-416Informations de copyright
©by Acta Endocrinologica Foundation.
Références
Genes Dev. 2010 Oct 1;24(19):2115-26
pubmed: 20889712
J Clin Endocrinol Metab. 2003 Aug;88(8):3694-9
pubmed: 12915657
Jpn J Cancer Res. 1999 Sep;90(9):977-81
pubmed: 10551327
World J Oncol. 2010 Dec;1(6):221-231
pubmed: 29147212
J Clin Endocrinol Metab. 2001 Feb;86(2):656-8
pubmed: 11158026
Am J Clin Pathol. 2016 Nov 1;146(5):594-602
pubmed: 27806941
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18363-70
pubmed: 18000042
J Invest Dermatol. 2006 Oct;126(10):2167-77
pubmed: 16983326
Clin Cancer Res. 2002 May;8(5):1125-31
pubmed: 12006528
Int J Exp Pathol. 2007 Aug;88(4):271-7
pubmed: 17696908
Br J Cancer. 2000 Oct;83(7):887-91
pubmed: 10970690
J Endocrinol. 1999 Apr;161(1):41-9
pubmed: 10194527
Clin Cancer Res. 1999 Jul;5(7):1823-9
pubmed: 10430087
Clin Cancer Res. 2005 Nov 15;11(22):8063-9
pubmed: 16299237
Hum Pathol. 2013 Oct;44(10):2204-12
pubmed: 23845470
Crit Rev Oncol Hematol. 2015 Apr;94(1):45-54
pubmed: 25560732
Clin Cancer Res. 2000 May;6(5):1900-8
pubmed: 10815914
Exp Cell Res. 2006 Mar 10;312(5):549-60
pubmed: 16336962
Theriogenology. 2014 Feb;81(3):428-36
pubmed: 24246422